Evidence map›Paper›PMID 30354399›Full record

ArticleCirculation. Heart failure2018

IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure.

James L Januzzi, Milton Packer, Brian Claggett, Jiankang Liu, Amil M Shah, Michael R Zile, Burkert Pieske, Adriaan Voors, Parul U Gandhi, Margaret F Prescott and 4 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation. Heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00887588 (A 36-week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction), which is not on this map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00887588 phase2completednot on this map

A 36-week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

TypeinterventionalSponsorNovartis PharmaceuticalsRan2009 to 2011Enrolled307ConditionsChronic Heart FailureArmsLCZ696, Valsartan, Placebo
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 71 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 5 countries.

James L JanuzziDivision of Cardiology, Massachusetts General Hospital, Boston (J.L.J.).
Milton PackerDivision of Cardiology, Baylor University Medical Center, Dallas, TX (M.P., S.D.S.).
Brian ClaggettDivision of Cardiology, Brigham and Women's Hospital, Boston, MA (B.C., J.L., A.M.S.).
Jiankang LiuDivision of Cardiology, Brigham and Women's Hospital, Boston, MA (B.C., J.L., A.M.S.).
Amil M ShahDivision of Cardiology, Brigham and Women's Hospital, Boston, MA (B.C., J.L., A.M.S.).
Michael R ZileDivision of Cardiology, Medical University of South Carolina, Charleston (M.R.Z.).
Burkert PieskeDivision of Cardiology, Charite Hospital, Berlin, Germany (B.P.).
Adriaan VoorsDivision of Cardiology, University Medical Center Groningen, The Netherlands (A.V.).
Parul U GandhiDivision of Cardiology, Yale University Medical Center, New Haven, CT (P.U.G.).
Margaret F PrescottNovartis Pharmaceutical Corporation, Hanover, NJ (M.F.P., V.S., M.P.L.).
Victor ShiNovartis Pharmaceutical Corporation, Hanover, NJ (M.F.P., V.S., M.P.L.).
Martin P LefkowitzNovartis Pharmaceutical Corporation, Hanover, NJ (M.F.P., V.S., M.P.L.).
John J V McMurrayDivision of Cardiology, University of Glasgow, United Kingdom (J.J.V.M.).
Scott D SolomonDivision of Cardiology, Baylor University Medical Center, Dallas, TX (M.P., S.D.S.).
Brigham and Women's Hospital · USNovartis (Switzerland) · CHBaylor University Medical Center · USCharité - Universitätsmedizin Berlin · DEJohn Caunt Scientific (United Kingdom) · GBMassachusetts General Hospital · USMedical University of South Carolina · USUniversity Medical Center Groningen · NLYale Cancer Center · US

Funding

Mapping the Progression to HFpEF in the Elderly through Longitudinal Changes in Cardiac FunctionR01HL135008 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI Amil M Shah · 2017 to 2026
$11.5M
Mentoring patient-oriented research in deep phenotyping of cardiac function for heart failure preventionK24HL152008 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAH, AMIL M · 2020 to 2024
$608k
NHLBI NIH HHS K24 HL152008NHLBI NIH HHS R01 HL135008
6 · The paper itself

Abstract

backgroundIncreased activity of IGFBP7 (insulin-like growth factor-binding protein-7) is associated with cellular senescence, tissue aging, and obesity. IGFBP7 may be related to heart failure with preserved ejection fraction, a disease of elderly obese people. METHODS AND

resultsIn a subset of patients with heart failure with preserved ejection fraction (N=228) randomized to receive sacubitril/valsartan versus valsartan, IGFBP7 concentrations were measured at baseline, 12 weeks, and 36 weeks. Patient characteristics and echocardiographic measures including left atrial (LA) size and volume, ratio of early mitral inflow velocity/annular diastolic velocity, and ratio of early diastole/peak late diastolic velocity were assessed as a function of IGFBP7 concentration. Effect of sacubitril/valsartan on IGFBP7 concentrations was analyzed. With increasing baseline IGFBP7 quartiles, LA size and LA volume index (LAVi) were higher (both P<0.001); modest association between IGFBP7 and higher early mitral inflow velocity/annular diastolic velocity ( P=0.03) and early diastole/peak late diastolic velocity ratio ( P=0.04) was also seen. IGFBP7 concentrations were higher in those with LAVi ≥34 mL/m

conclusionsAmong patients with heart failure with preserved ejection fraction, concentrations of the cellular senescence biomarker IGFBP7 were associated with abnormalities in diastolic filling and LA dilation. Treatment with sacubitril/valsartan resulted in lower IGFBP7 concentrations compared with valsartan. CLINICAL

trial registrationURL: https://www.clinicaltrials.gov . Unique identifier: NCT00887588.

Indexed as

AgedAged, 80 and overAngiotensin Receptor AntagonistsBiomarkersFemaleHeart FailureHumansInsulin-Like Growth Factor Binding ProteinsMaleMiddle AgedNeprilysinStroke VolumeValsartanAngiotensin Receptor AntagonistsBiomarkersinsulin-like growth factor binding protein-related protein 1Insulin-Like Growth Factor Binding ProteinsNeprilysinValsartanatrial fibrillationbiomarkersechocardiographyheart failurevalsartan

Identifiers

PMID30354399
PMCPMC12611560
OpenAlexW2896431240

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.